Effects of Coenzyme Q10 on Markers of Inflammation: A Systematic Review and Meta-Analysis

PLoS One. 2017 Jan 26;12(1):e0170172. doi: 10.1371/journal.pone.0170172. eCollection 2017.

Abstract

Background/objective: Chronic inflammation contributes to the onset and development of metabolic diseases. Clinical evidence has suggested that coenzyme Q10 (CoQ10) has some effects on inflammatory markers. However, these results are equivocal. The aim of this systematic review was to assess the effects of CoQ10 on serum levels of inflammatory markers in people with metabolic diseases.

Methods: Electronic databases were searched up to February 2016 for randomized controlled trials (RCTs). The outcome parameters were related to inflammatory factors, including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α) and C reactive protein (CRP). RevMan software was used for meta-analysis. Meta-regression analysis, Egger line regression test and Begg rank correlation test were performed by STATA software.

Results: Nine trials involving 428 subjects were included in this meta-analysis. The results showed that compared with control group, CoQ10 supplementation has significantly improved the serum level of CoQ10 by 1.17μg/ml [MD = 1.17, 95% CI (0.47 to 1.87) μg/ml, I2 = 94%]. Meanwhile, it has significantly decreased TNF-α by 0.45 pg/ml [MD = -0.45, 95% CI (-0.67 to -0.24) pg/ml, I2 = 0%]. No significant difference was observed between CoQ10 and placebo with regard to CRP [MD = -0.21, 95% CI (-0.60 to 0.17) mg/L, I2 = 21%] and IL-6 [MD = -0.89, 95% CI (-1.95 to 0.16) pg/ml, I2 = 84%].

Conclusions: CoQ10 supplementation may partly improve the process of inflammatory state. The effects of CoQ10 on inflammation should be further investigated by conducting larger sample size and well-defined trials of long enough duration.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Biomarkers / blood
  • C-Reactive Protein / metabolism*
  • Dietary Supplements
  • Electronic Health Records
  • Humans
  • Inflammation / blood*
  • Inflammation / diet therapy
  • Inflammation / pathology
  • Interleukin-6 / blood*
  • Randomized Controlled Trials as Topic
  • Tumor Necrosis Factor-alpha / blood*
  • Ubiquinone / analogs & derivatives*
  • Ubiquinone / blood
  • Ubiquinone / therapeutic use

Substances

  • Biomarkers
  • IL6 protein, human
  • Interleukin-6
  • Tumor Necrosis Factor-alpha
  • Ubiquinone
  • C-Reactive Protein
  • coenzyme Q10

Grant support

The authors received no specific funding for this work.